Anacor Pharmaceuticals to Host Investor Day in New York

  Anacor Pharmaceuticals to Host Investor Day in New York

Business Wire

PALO ALTO, Calif. -- July 30, 2013

Anacor Pharmaceuticals (NASDAQ:ANAC) will host an Investor Day for
institutional investors and research analysts on Monday August 5, 2013 from
approximately 12:00 p.m. to 3:30 p.m. ET in New York, New York. The meeting
will focus on the development of its two lead compounds - tavaborole for
onychomycosis and AN2728 for atopic dermatitis. Experts in the fields of
podiatry and dermatology will be featured speakers at the meeting.

A live webcast of the event will be available on the Investor Relations page
of Anacor’s website at www.anacor.com.

For more information, contact DeDe Sheel, Anacor Pharmaceuticals Director of
Investor Relations and Corporate Communications. dsheel@anacor.com.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, a topical antifungal for the treatment of
onychomycosis, and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to tavaborole and
AN2728, respectively, and AN3365 an antibiotic for the treatment of infections
caused by Gram-negative bacteria. We have discovered three other compounds
that we have out-licensed for further development — two compounds for the
treatment of animal health indications that are licensed to Eli Lilly and
Company and AN5568, also referred to as SCYX-7158, for human African
trypanosomiasis (HAT, or sleeping sickness), which is licensed to Drugs for
Neglected Diseases initiative, or DNDi. We also have a pipeline of other
internally discovered topical and systemic boron-based compounds in
development. For more information, visit http://www.anacor.com.

Contact:

Anacor
DeDe Sheel, 650-543-7575
Investor Relations and Corporate Communications
dsheel@anacor.com
 
Press spacebar to pause and continue. Press esc to stop.